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Abstract
abYsis is a web-based antibody research system that includes an integrated
database of antibody sequence and structure data. The system can be inter-
rogated in numerous ways — from simple text and sequence searches to so-
phisticated queries that apply 3D structural constraints. The publicly available
version includes pre-analysed sequence data from EMBL-ENA and Kabat as
well as structure data from the PDB. A researcher’s own sequences can also be
analysed through the web interface.
A defining characteristic of abYsis is that sequences are automatically num-
bered with a series of popular schemes such as Kabat and Chothia and then
annotated with key information such as CDRs and potential post-translational
modifications. A unique aspect of abYsis is a set of residue frequency tables for
each position in an antibody, allowing ‘unusual residues’ (those rarely seen at a
particular position) to be highlighted and decisions to be made on which muta-
tions may be acceptable. This is especially useful when comparing antibodies
from different species.
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abYsis is useful for any researcher specializing in antibody engineering, es-
pecially those developing antibodies as drugs.
abYsis is available at www.abysis.org.
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1. Research highlights
• abYsis is a web-based antibody research system which integrates sequence
data from EMBL-ENA and Kabat with sequence and structure data from
the PDB.
• It allows searches based on text, sequence data and structural constraints.
• It automatically numbers sequences and provides detailed annotations to
aid interpretation.
• Users can upload and analyze their own sequences in the same way via
the web interface.
• It provides a comprehensive set of position and species-specific residue
distributions.
• Additional advanced tools are provided to assess antibody characteristics
such as humanness.
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2. Graphical Abstract
3. Introduction
Antibodies are amongst the most important classes of proteins involved in
the adaptive immune system. They act as adapter molecules between the virtu-
ally infinite range of possible antigens and the constant effector molecules such
as Fc receptors and C1q of the complement system. Through DNA-level splicing
of V and J gene segments in the light chain and V, D and J gene segments in the
heavy chain, they create a repertoire of around 1011 possible sequences[1]. The
fact that antibodies are capable of binding to a virtually infinite set of antigens,
generally with high specificity and affinity, has led to a huge interest in using
them as drugs in the treatment of human disease[2].
Therapeutic antibodies can act through a variety of mechanisms. First, they
may act simply to bind to a target in the way that most small-molecule drugs
3
work. For example, they may bind to receptors acting as agonists or antago-
nists, or to enzymes acting as inhibitors or as allosteric activators. Since they
have a much larger interacting surface than typical small-molecule drugs (which
generally bind into pockets on a protein surface), they can also interact with
much flatter protein surfaces and can therefore be used to bind to hormones or
disrupt protein-protein interactions. Second, antibodies can be used to trigger
the immune system in the normal way to kill cells such as tumour cells or virus-
infected cells. For example, the antibody, Palivizumab (Synergis), is used to
prevent respiratory syncytial virus (RSV) infection in high-risk infants. Third,
antibodies can be used as a delivery mechanism, either through antibody-drug
conjugates with cytotoxic moieties or through ‘antibody-directed enzyme pro-
drug therapy’ (ADEPT), which aims to restrict the action of a cytotoxic drug
to cancer sites[3]. Fourth, more recent developments have led to bispecific anti-
bodies capable of binding two antigens, either for convenience of having a single
agent, or deliberately cross-linking different molecules[4, 5, 6].
It has been estimated that around a third of all drugs in development are
monoclonal antibodies[7, 8] and as of May 2016, according to the Antibody
Society, 55 monoclonal antibody products had been approved in the US or
Europe with around four new products being approved per year[9]. Therapeutic
antibodies have been used for a wide variety of conditions such as cancer[10],
transplant rejection[11], rheumatoid arthritis[12], antiviral prophylaxis[13] and
Crohn’s disease[14].
Despite the success of antibodies in the clinic, there are a number of problems
in developing successful therapeutics. As well as high affinity and specificity, an-
tibodies must be non-immunogenic and have sufficiently high bio-availability. In
addition, stability is important to avoid denaturation and aggregation, not only
for long shelf-life and persistent bio-availability, but also because denaturation
and aggregation can lead to increased immunogenicity[15, 16, 17]. Consequently
there is still room for improvement in building better antibodies having higher
affinity and lower immunogenicity[18].
Traditionally, producing fully human antibodies has been difficult while an-
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tibodies from other species are likely to lead to an immune reponse (the ‘Human
Anti-Mouse Antibody’ (HAMA) response[19, 20], or more generally the ‘Anti-
Antibody Response’, AAR[21]). This prevents repetitive administration of the
antibody for treatment and may lead to anaphylactic shock. Traditional meth-
ods for producing monoclonal antibodies[22] do not work in humans[23, 24].
Techniques such as SLAM[25] allow screening of B cells harvested from periph-
eral blood, spleen, bone marrow or lymph nodes and, as well as being applicable
to non-human species, can be used to identify therapeutic antibody candidates
from human peripheral blood. While this can be useful for creating anti-infective
agents, the majority of targets are human proteins against which humans do not
produce an immune response. While the production of antibodies from phage-
display libraries has been very popular[26, 27], the success of these agents in
the clinic has so far been limited. Another more recent development is the
production of fully human antibodies from transgenic mice[23] where the anti-
body repertoire is fully human, but this route is extremely expensive. Conse-
quently murine (or other non-human) antibodies are frequently engineered to
make them appear ‘more human’. The process of humanization aims to reduce
immunogenicity of non-human antibodies by using human constant and variable
regions as an ‘acceptor’ into which non-human CDRs from the ‘donor’ antibody
with the required specificity are inserted[28, 29]. However, in general na¨ıvely
grafted antibodies do not bind well and some framework residues need to be
‘back-mutated’ to the equivalent donor residue in order to restore the binding
affinity[30].
Despite the interest in antibodies and the need to engineer them, the
range of freely available web-based tools and resources to aid in this process
is limited. Probably the best known resource is IMGT[31], a comprehensive
collection of data and services available over the web. There are a number
of web-based antibody modelling servers, the performance of which was
recently compared in the second antibody modeling assessment (AMA-II)[32].
These include PiGS[33], (www.biocomputing.it/pigs), SAbPred[34]
(opig.stats.ox.ac.uk/webapps/sabdab-sabpred/WelcomeSAbPred.php),
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Total sequences in EMBLIG 127450
Total sequences in IMGT 96970
Total sequences present in both datasets 91898
Total missing from EMBLIG that are present in IMGT 5072
Total missing from IMGT that are present in EMBLIG 35552
Table 1: Comparison of the data in IMGT (release 16Jul2016) and EMBLIG (release
18Apr2016). Sequences in IMGT are filtered to include only antibody variable domain se-
quences derived from EMBL-ENA. Both datasets were filtered to ensure that translations
were at least 50 residues in length.
Rosetta Antibody[35, 36], Kotai Antibody Builder[37] (kotaiab.org)
and SmrtMolAntibody[38] (www.macromoltek.com). SAbPred also
includes antibody numbering[39] and epitope and paratope prediction.
Other resources include SAbDab[40], a database of antibody structures,
(opig.stats.ox.ac.uk/webapps/sabdab-sabpred/Welcome.php),
Tabhu, a set of tools to aid with antibody humanization[41]
(circe.med.uniroma1.it/tabhu/) and Digit[42], a database of antibody
variable domain sequences (circe.med.uniroma1.it/digit/).
For many years we have offered a number of web-based antibody tools
including KabatMan[43], SACS[44], AbNum[7], expressed-sequence-scored
humanness[45], germline-scored humanness[46], VH/VL packing-angle
prediction[47], assignment of Chothia canonical classes[48] and testing
a sequence for unusual residues[43]. These are all available via
www.bioinf.org.uk/abs/.
Here we describe our abYsis system, a database of antibody sequence and
structure which also integrates many of the analysis tools described above.
4. Results
abYsis contains antibody protein sequences from EMBLIG which contains
antibody information extracted from the EMBL-ENA databank (Couch, Porter,
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Data Protein Sequences Classified
Sources Sequences ≥70aa Numbered Total Heavy Light Paired
EMBLIG 126422 119422 101969 122745 92179 30566 3555
Kabat 19399 14114 12631 19399 11842 7557 2572
PDB 7712 7712 7534 7534 3820 3714 3397
Total 153533 141248 122134 149678 107841 41837 9524
Table 2: Processed content of the abYsis database as of May 2016. In addition, DNA data
are available for sequences from EMBLIG and Kabat. The NCBI Germline data and germline
information from V-BASE are also included.
Swindells and Martin, in preparation), the Kabat collection[49] (which has not
been updated since July 2000), and the Protein Databank (PDB)[50]. Data
from other sources such as IMGT can also be loaded, but the vast majority of
sequence information in IMGT is contained in EMBLIG or the PDB which we
handle separately. In fact, EMBLIG contains many antibody sequences that are
not present in IMGT. Comparing the two datasets as described in the Materials
and Methods, we found that the two datasets overlap by 28,388 sequences.
EMBLIG contains 94.8% of the sequences in IMGT, but 27.9% of sequences in
EMBLIG were not present in IMGT; EMBLIG contains 1.3× more sequences
than IMGT. See Table 1.
The ability to integrate data from other sources is particularly useful for
people who decide to have abYsis in-house as they can include their own se-
quence data in the resource. Table 2 shows the processed content of the latest
release of abYsis (V2.7.3) as of May 2015. Automated numbering of sequences
using abnum[7] is key to the annotation of sequences — the current release
successfully numbers 122,134 sequences. The system also provides automated
pairing of light and heavy chains. Resources such as EMBL-ENA (and therefore
EMBLIG) and Kabat do not contain a clear pairing field to link data for light
and heavy chains, although a ‘DR/partner’ field is being populated in IMGT
and we exploit this when reading IMGT data. Consequently, as described in
the Materials and Methods, we attempt to take a cautious approach to pairing
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for other data sources. For EMBLIG data, we use the clone information to per-
form the pairing: 7,110 chains are paired into 3,555 antibodies while antibodies
containing a single chain occur 119,312 times because this clone information
is only present for ∼56% of chains in EMBLIG. The most highly represented
species are Homo sapiens (88,662), Mus musculus (41,254), Macaca mulatta
(3,561), Oryctolagus cuniculus (2,668), Equus caballus (1,138), Oncorhynchus
mykiss (979), Lama glama (955), Camelus dromedarius (930), Ginglymostoma
cirratum (893), with synthetic constructs coming in fourth place with 2,968
entries.
The reason that numbering is key to the annotation is that it enables us to
identify regions of the sequences (CDRs and frameworks). It provides an implicit
sequence alignment (which can be displayed in abYsis using JSAV[51]) and
mapping of sequence to structure allowing us to look at the frequency of residue
types at each position and to identify key residues that define the conformation
of the CDRs[52] or which are important in antibody humanization[30, 53].
abYsis can be used in three main ways: a) by searching the database to
find information about sequences (and structures) including detailed annota-
tions, identification of unusual residues, post-translational modification sites,
etc., b) by analyzing trends across sequences in the database and c) by entering
your own sequences for analysis. These three approaches are described below.
4.1. Searching the database
The main search page allows searches based on identifiers, names, antigens
(where described and parsable in the source data), references, authors, organ-
isms, etc., and searches can be restricted to a given dataset (PDB, Kabat, EM-
BLIG, or other datasets that have been included) or to a given class of chain. In
addition, searches can be structure-based by requiring CDRs to match specific
canonical classes or specifying residues within a given distance of a particular
position; for example, one could find all antibodies with a lysine within 4A˚ of
residue L23. This can be done either in known structures or by using averaged
distances calculated across all known structures to extrapolate these constraints
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Figure 1: Simple searches of abYsis. On the left is the main search page showing the default
simple options. Searching for ‘hyhel’ in the Name field results in a table of hits shown upper
right. For clarity, this has been truncated — the full view would show the complete information
for the light chains to the right of the heavy chains where paired sequences have been found.
Bottom right shows the alignment view of the sequences.
to sequences for which no structure is available. Finally one can also search on
the basis of sequence. Searches can specify motifs (either exact or using reg-
ular expressions) present throughout the sequence or within particular regions
(CDRs, frameworks), region lengths, or residues present or not present at par-
ticular positions.
A simple example search is shown in Figure 1 together with two views of
the results — as a simple table or as a sequence alignment. The results come
from searching for ‘hyhel’ and therefore displaying the HyHEL set of antibodies
binding to hen egg white lysozyme described by Smith-Gill and colleagues[54].
Having selected a particular sequence of interest, much more detailed infor-
mation is provided in what we term the ‘Key Annotation’ page which provides
a set of tabs with different information. The initial summary page provides
the sequence with Chothia numbering applied and the Chothia structural loops
highlighted. Unusual residues occurring in < 1% of sequences across all species
are highlighted as are a range of predicted post-translational modification sites.
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Figure 2: Key annotation results for the heavy chain of antibody HyHEL-5. a) the ‘Numbering
& Regions’ tab — unusual residues are highlighted with an upwards arrow, predicted CK2
phosphorylation sites with a gear wheel and predicted PKC phosphorylation sites with a
lightning symbol; b) the ‘Humanize’ tab.
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Information about the sequence (accession code, data source, dates, name, or-
ganism, chain type, partner chain and references) is also provided. A button at
the bottom of the page allows the sequence to be searched against all the other
sequences using BLAST.
The ‘Numbering & Regions’ tab (part of which is shown in Figure 2a) gives
more control over numbering schemes allowing Kabat, Chothia, or Martin (En-
hanced Chothia)[7] schemes as well as displaying CDRs / structural loops ac-
cording to definitions provided by Kabat, Chothia, AbM (useful for modelling
purposes) and contacts[55]. On the right of the panel is shown a residue distri-
bution graph for the currently selected residue — in this case residue H1. As
the graph shows, the most common residues (across all species) are glutamate
(E) and glutamine (Q); the amino acid present in this particular sequence is
highlighted with an arrow above the relevant bar.
The ‘Unusual Residues’ tab allows the same information to be provided, but
allows the comparison to be restricted to a specific species, while the ‘Human-
ization’ tab gives a much more detailed view of this information. Again clicking
on an amino acid will show a graph of its distribution which can be restricted to
a particular species. The ‘heatmap’ which is part of the humanization tab and
shown in part in Figure 2b, gives a summary of the graphical view of residue
frequencies for each position in the sequence. Two thresholds are defined using
sliders at the bottom of the page; for each position, amino acid types with a fre-
quency below the lower threshold (i.e. unusual residues) are shown in red, those
above the higher threshold (i.e. common) are shown in green with the remaning
residues shown in yellow, the CDRs being shown in darker shades. At the top
of the heatmap, the sequence is shown with colours based on a first reference
sequence and then with colours against a second reference sequence which is
also used for the rest of the heatmap. Clicking on a residue in the middle of
the heatmap will update the sequence shown at the bottom which can then be
exported. Typically one might set mouse as the first reference and human as
the second reference thus allowing the identification of unusual human residues.
Other tabs provided include a) assignment of Chothia conformational canoni-
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Figure 3: Distributions of CDR-H3 lengths in a) humans, b) mice, c) rats, d) camel, e) rabbit
and f) chicken.
cal classes based on sequence; b) a ‘Structure’ tab, only displayed if the selected
sequence comes from a PDB file, in which the structure can be viewed and
rotated; c) a ‘Germline’ tab which maps a sequence to the closest germline
sequences; and d) a ‘Humanness’ tab which implements the method of Abhi-
nandan and Martin for assessing how human-like a sequence is[45].
4.2. Analyzing trends
The distributions search page allows the distributions of residues at partic-
ular positions to be analyzed outside the context of a particular sequence. It
also allows distributions of the lengths of regions (CDRs and frameworks) to
be analyzed. This has been an area of some considerable previous interest. For
example, Wu et al.[56] analyzed the distribution of the lengths of CDR-H3 loops
in humans and other species and concluded that ‘human sequences vary from 2
to 26 amino acids residues, but less extensively in other species’. They updated
their analysis in 1993[57] refining the analysis in an attempt to look at defined
specficities. Similar detailed analyses of length distributions were performed by
Collis et al.[58] and Barrios et al.[59].
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Such analyses become straightforward using abYsis and in Figure 3 we show
the length distributions of CDR-H3 in humans, mice, rats, camel, rabbit and
chicken. The graph confirms earlier observations that mouse antibodies tend
to have shorter CDR-H3 lengths than humans, but also shows that this trend
extends to rat antibodies. Despite the recent popularity of rabbit antibodies
in generating potential clinical antibodies, the CDR-H3 lengths still tend to be
shorter than human antibodies, but camels and chickens tend to have CDR-H3s
that are even longer than humans.
4.3. Entering your own sequences
The sequence input pages allow one or more protein and/or DNA sequences
to be entered. These are numbered and analyzed in exactly the same way
as sequences stored in the database. Consequently all the ‘key annotation’
information described above is also available for these. Sequences can also be
searched against the database using BLAST to find the most similar antibodies.
The ‘Humanization’ tab is of particular interest since it allows one to upload
a na¨ıvely humanized antibody (i.e. where the CDRs have been grafted from a
donor species onto a human acceptor framework) and compare this with unusual
residues identified in the mouse framework which may be functionally important.
One can also look for unusual residues in the human acceptor which may have
an effect on binding or lead to immunogenicity.
The locally-installed version of abYsis also allows sequences to be uploaded
and added to the database.
5. Materials and Methods
abYsis is based around a PostgreSQL relational database populated with
sequence and structure data. All sequences are numbered using Kabat, Chothia
and Martin numbering schemes using abnum[7] and the database is populated
using scripts written in Perl. The web interface is implemented using Perl and
Mason and the Javascript Sequence Alignment Viewer (JSAV)[51] is used to
display sequence alignments. JSmol[60] is used for structure display.
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5.1. Comparison of EMBLIG and IMGT
A Perl script was written to compare the content of EMBLIG and IMGT.
The IMGT data file contains sequences that are not antibodies and, while mostly
coming from EMBL-ENA also comes from sources such as the PDB (that we
treat separately). Consequencely the IMGT data were filtered to ensure that
the sequence a) was present in EMBL-ENA, b) was labelled as IG-Light or IG-
Heavy, c) contains a variable domain, d) has a translation provided of at least
50 residues, e) is not a pseudogene. EMBLIG data were also filtered to include
only sequences with translations of at least 50 residues.
5.2. Pairing antibody chains
For Kabat data, we pair antibody chains based on the provided ‘name’
field and author information to pair light and heavy chains as described by
Martin[43]. For pairing chains within PDB files, we examine the proximity of
residues normally found in the interface between light and heavy chains. For
EMBLIG data derived from EMBL-ENA, there is no clear name field so we
currently use the clone name given in the ‘FT/source/clone=’ field. As well
as matching the clone name, pairs of light and heavy chains must also share
publication data.
6. Conclusion
abYsis provides a unique integrated web-based environment for exploring
antibody sequence and structure, bringing together data from different public
sources. In addition, users who install the system locally are able to integrate
their own sequence data. A key advantage of abYsis is that we try to pair light
and heavy chain sequences. However, we take a cautious approach to this and,
in the case of EMBLIG data derived from EMBL-ENA, we use clone information
that is only present for ∼56% of chains. Consequently, future work will include
exploiting information in the ‘FT/CDS/product=’ information which is used to
provide a ‘Name’ in abYsis. However this will require cleanup to remove unin-
formative text (such as ‘immunoglobulin’, ‘gamma’, ‘heavy’, ‘light’ or ‘chain’)
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and, for safety, would need to be combined with author and/or publication in-
formation. The system provides annotation of sequences stored in the system,
or which a user uploads, and allows individual sequences to be compared with
those in the underlying database. Integration of sequence and structure data
allows analysis of sequence data in a structural context and the system provides
tools that can aid with antibody engineering.
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